INT_767



NAME OF DRUG : INT_767

ALSO KNOWN AS : INT_767

LABORATORY : INTERCEPT

STATUS AND ADVANCEMENT

Type of drug : farnesoid X receptor (FXR) and TGR5, a G-protein coupled bile acid receptor

Clinical trials advancement : Ongoing Phase 1

Estimated time to market : 131 months.

LABORATORY ABSTRACT ON THE DRUG

INT-767 is Intercept’s second bile acid analog to enter phase 1 clinical development INT-767 is a more potent FXR agonist than obeticholic acid (OCA), Intercept’s lead product candidate, and has the potential to demonstrate greater efficacy in liver disease INT-767 also activates TGR5, a second bile acid receptor. TGR5 has been shown to affect energy metabolism, glucose homeostasis, bile composition/secretion, and inflammation In animal models, INT-767 has shown the potential to both prevent and reverse organ damage due to fibrosis

HISTORY AND ANALYSIS

Nov 1, 2017  Intercept announced that they has decided to deprioritize its INT-767 development program for the foreseeable future.

 

RECENT NEWS ON INT_767

SOME PUBLICATIONS RELATED WITH INT_767

January 2017 : Mice species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15 (necessity to monitor HCC risk with FXR agonists )

February 2013 : Dual actions of fibroblast growth factor 19 on lipid metabolism

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH INT_767


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE